- Abivax (NASDAQ:ABVX) received positive pre-NDA feedback from the U.S. FDA for its lead product, Obefazimod, signaling progress in its therapeutic development.
- Despite a recent price target adjustment by Wedbush, analysts maintain a “Moderate Buy” consensus rating for Abivax, projecting an average one-year price target of $156.38.
- The company boasts a robust financial position with €402.40 million in cash and short-term investments, supplemented by a recent €767.10 million offering, ensuring a cash runway into the fourth quarter of 2029.
Abivax (NASDAQ:ABVX) is a Paris-based company developing new therapies. It recently announced a positive pre-NDA interaction with the U.S. FDA for its product, Obefazimod. As highlighted by Benzinga, analysts expect Abivax to report a loss of $1.08 per share on revenue of $1.86 million for its first-half 2026 earnings.
On September 22, 2026, analyst firm Wedbush lowered its price target for Abivax to $118. A price target is an analyst’s projection of a stock’s future price. At the time, the stock was trading at $103.45. This new target suggests a potential upside, or increase in value, of approximately 14.1% from that price.
Despite this specific adjustment, the overall analyst view is positive. As reported by MarketBeat.com, Abivax has a “Moderate Buy” consensus rating from sixteen research firms. The average one-year price target among these analysts is $156.38. This includes a “buy” rating from The Goldman Sachs Group with a $155.00 target price.
Abivax has a strong financial position. It reported cash and short-term investments of €402.40 million as of June 30, 2026. A recent offering of shares provided an additional €767.10 million. This gives Abivax a cash runway, or enough money to fund operations, into the fourth quarter of 2029 without needing more funds.
Abivax is also preparing for future growth by strengthening its leadership team. Abivax appointed a new Chief Medical Officer and a new Chief Technical Officer. A recent buy-back of royalty certificates also reduces its future payment obligations, giving it more financial flexibility for commercialization efforts.
